Emory University Raises Position in Zogenix, Inc. (ZGNX)

Emory University increased its position in shares of Zogenix, Inc. (NASDAQ:ZGNX) by 26.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 224,820 shares of the company’s stock after buying an additional 46,979 shares during the period. Zogenix comprises about 2.3% of Emory University’s holdings, making the stock its 4th largest position. Emory University’s holdings in Zogenix were worth $2,439,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZGNX. Dimensional Fund Advisors LP increased its position in Zogenix by 101.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 216,814 shares of the company’s stock worth $2,634,000 after buying an additional 109,134 shares during the last quarter. A.R.T. Advisors LLC bought a new position in Zogenix during the fourth quarter worth about $154,000. Baker BROS. Advisors LP bought a new position in Zogenix during the third quarter worth about $11,430,000. Senzar Asset Management LLC bought a new position in Zogenix during the fourth quarter worth about $1,921,000. Finally, Candriam Luxembourg S.C.A. increased its position in Zogenix by 62.0% in the first quarter. Candriam Luxembourg S.C.A. now owns 243,000 shares of the company’s stock worth $2,637,000 after buying an additional 93,000 shares during the last quarter. Institutional investors own 87.10% of the company’s stock.

Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

Zogenix, Inc. (NASDAQ:ZGNX) traded up 1.39% during trading on Friday, reaching $14.60. 580,405 shares of the company traded hands. The firm’s market capitalization is $362.27 million. The company’s 50-day moving average price is $12.98 and its 200 day moving average price is $11.29. Zogenix, Inc. has a 52 week low of $7.33 and a 52 week high of $15.20.

Zogenix (NASDAQ:ZGNX) last issued its quarterly earnings data on Thursday, May 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.88) by $0.03. Zogenix had a negative return on equity of 57.74% and a negative net margin of 360.89%. The business had revenue of $2.70 million for the quarter, compared to analysts’ expectations of $4.23 million. During the same period in the prior year, the firm earned ($0.42) EPS. The company’s revenue for the quarter was down 70.7% on a year-over-year basis. On average, equities research analysts expect that Zogenix, Inc. will post ($3.63) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/06/16/zogenix-inc-zgnx-is-emory-universitys-4th-largest-position-updated-updated.html.

Several research analysts have weighed in on ZGNX shares. Aegis restated a “buy” rating and set a $28.00 price objective on shares of Zogenix in a report on Saturday, March 11th. Zacks Investment Research lowered shares of Zogenix from a “buy” rating to a “hold” rating in a research note on Wednesday, March 15th.

Zogenix Company Profile

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply